KPLH1130 is a selective pyruvate dehydrogenase kinase (PDK) inhibitor that improves glucose tolerance in high-fat diet-fed mice. Its mechanism involves suppressing macrophage polarization and pro-inflammatory responses, making it a useful research tool for studying metabolic inflammation in both in vivo and in vitro models.
